본문으로 건너뛰기
← 뒤로

Prognostic value of manual and digital PD-L1 expression in pT3 and pT4 colon cancer.

1/5 보강
Diagnostic pathology 📖 저널 OA 95.2% 2022: 1/1 OA 2023: 4/4 OA 2024: 1/1 OA 2025: 19/19 OA 2026: 12/14 OA 2022~2026 2025 Vol.20(1) p. 135
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
162 patients with pT3 and pT4 CC were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This exploratory study aimed to evaluate PD-L1 expression using manual and digital methods and correlate the results to overall survival (OS) in a cohort of patients with pT3 and pT4 colon cancer (CC).

Jepsen DNM, Jensen MB, Bennedsen ALB, Grantzau TL, Eriksen TT, Eriksen JO, Bzorek M, Gögenur I, Fiehn AK

📝 환자 설명용 한 줄

[BACKGROUND] Programmed death ligand 1 (PD-L1) is a prognostic marker in several malignancies, but the prognostic value of PD-L1 expression in colorectal cancer (CRC) is inconclusive.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p = 0.018
  • p-value p = 0.049

이 논문을 인용하기

↓ .bib ↓ .ris
APA Jepsen DNM, Jensen MB, et al. (2025). Prognostic value of manual and digital PD-L1 expression in pT3 and pT4 colon cancer.. Diagnostic pathology, 20(1), 135. https://doi.org/10.1186/s13000-025-01735-x
MLA Jepsen DNM, et al.. "Prognostic value of manual and digital PD-L1 expression in pT3 and pT4 colon cancer.." Diagnostic pathology, vol. 20, no. 1, 2025, pp. 135.
PMID 41272706 ↗

Abstract

[BACKGROUND] Programmed death ligand 1 (PD-L1) is a prognostic marker in several malignancies, but the prognostic value of PD-L1 expression in colorectal cancer (CRC) is inconclusive. Lack of standardized scoring systems for PD-L1 evaluation in CRC has led to inconsistent findings. This exploratory study aimed to evaluate PD-L1 expression using manual and digital methods and correlate the results to overall survival (OS) in a cohort of patients with pT3 and pT4 colon cancer (CC).

[METHODS] From a previously published study, 162 patients with pT3 and pT4 CC were included. One tumor slide representing the invasive margin was selected and stained for PD-L1 (22C3). PD-L1 was evaluated according to the tumor proportion score (TPS), the immune cell score (ICS), and the combined positive score (CPS). Additionally, a digital algorithm for detecting PD-L1 positive cells was developed. The manual and digital PD-L1 expression scores were correlated to OS in the entire cohort, and in subgroups according to mismatch repair (MMR) status.

[RESULTS] Only 1 case was classified with a TPS of ≥ 1%. The ICS was classified as < 1%, 1-9%, and ≥ 10% in 66%, 30.2% and 3.7% of the tumors, respectively. The CPS was classified as < 1, 1-9, and ≥ 10 in 82.7%, 15.4%, and 1.9% of the tumors, respectively. A high digital PD-L1 expression score was an independent prognostic factor for longer OS, adjusted for age, pT-category and adjuvant chemotherapy (aHR = 0.40, 95% CI = 0.19-0.86, p = 0.018). In the pMMR subgroup, both a CPS ≥ 1 and a high digital score were significantly associated with longer OS in the multivariate analyses (aHR = 0.24, 95% CI = 0.06-0.99, p = 0.049, and aHR = 0.34, 95% CI = 0.12-0.97, p = 0.043, respectively).

[CONCLUSIONS] Our results suggest that high PD-L1 expression is associated with longer OS. In future studies examining PD-L1 expression as a prognostic biomarker in CC, assessing PD-L1 expression using a digital approach or the CPS can be recommended.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기